Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
F. Chermiti Ben Abdallah, I. Zayani, A. Chtourou, S. Taktak, R. Mahouachi, A. Ben Kheder (Ariana, Tunisia). Allergic reactions to rifampicin in tuberculosis treatment. Eur Respir J 2011; 38: Suppl. 55, 4410

Member's Comments

No comment yet.

Related content which might interest you: Tolerance of cycloserine in combined therapy of tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001 Treatment results of cases of severe pulmonary tuberculosis with using rifabutin Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001 Manifestations of hypersensitivity to anti-tuberculosis drugs Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 High-dose rifampicin and rifapentine in tuberculosis treatment Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy Source: Eur Respir J 2005; 25: 324-328 Year: 2005 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Place of azoles in the treatment of allergic bronchopulmonary candidiasis Source: Eur Respir J 2006; 28: Suppl. 50, 52s Year: 2006 Adverse reactions in the treatment of patients with non-tuberculous pulmonary mycobacteriosis. Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease Year: 2021 Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013 Desensitization therapy for allergic reactions of antituberculous drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Adverse reaction of TB treatment with 2nd line drugs in a tuberculosis TB dispensary Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 Tuberculosis 1995–2004: evaluation of the resistance of mycobacterium tuberculosis to anti-TBC drugs in Greece Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 Adverse effects of moxifloxacin during tuberculosis treatment Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019 Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009 The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease Source: Eur Respir J 2015; 45: 1177-1179 Year: 2015 Adverse reactions to the tuberculosis treatment Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Source: Eur Respir J 2010; 35: 606-613 Year: 2010